Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted

- Phase 2 liquid suspension and Phase 1 lyophilized, non-frozen, oral capsules containing live microbes were studied in clinical trials; results are an important step in assessing investigational microbiome-based therapies.

Roseville, Minnesota, USA – May 17, 2019 – Rebiotix Inc., a Ferring company, will present data highlighting clinical trials of RBX2660 and RBX7455, two formulations of investigational microbiome restoration therapeutics being studied for the prevention of recurrent *Clostridioides* (*Clostridium*) *difficile* (C. diff) infection, at the 2019 Digestive Disease Week® (DDW) meeting, taking place May 18-21 in San Diego, California.

“There is a growing body of evidence that indicates the microbiome has great potential in fighting or reducing disease,” said Dr. Ken Blount, Chief Scientific Officer at Rebiotix. “One of the unmet needs, especially regarding recurrent C. diff infection, is the lack of standardized formulations that could be options for patients. We are excited to present the data from these two investigational trials, as we believe these findings are an important step in the assessment of investigational microbiome-based therapies.”

Details for the presentation are as follows:

- **Title:** Comparison of Two Open-Label Trials Demonstrates Similar 6-Month Outcomes For RBX2660 And RBX7455—Investigational Microbiota Restoration Therapeutics Administered By Enema Or Oral Capsules For Preventing Recurrent Clostridium Difficile Infections
- **Date, Time and Location:** Monday, May 20, 2019; Session 4305 in Room 29CD

About RBX2660 and RBX7455

RBX2660 is currently in Phase 3 clinical development for the prevention of recurrent *Clostridioides* (*Clostridium*) *difficile* (C. diff) infection. RBX2660 has been granted Fast Track, Orphan and Breakthrough Status designation from the U.S. Food and Drug Administration (US FDA). Rebiotix’s clinical pipeline also features RBX7455, a lyophilized, non-frozen, oral capsule part of a recently completed investigator-sponsored Phase 1 trial studied for the prevention of recurrent C. diff infection.

About Rebiotix

Rebiotix Inc., part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix has a diverse pipeline of investigational drug products built on its pioneering microbiota-based MRT™ drug platform. The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract. For more information on Rebiotix and its pipeline of human microbiome-directed therapies for diverse disease states, visit www.rebiotix.com.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Today, over one third of the company’s research and development investment goes towards finding innovative and personalized healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

For more information, please contact

Courtney Jones
Marketing Manager
+1 651 705-8774
cjones@rebiotix.com

GIMK/1374/2019/US